Tuberculosis, There New Hope for People with Tuberculosis
There is new hope for people with tuberculosis, a recent study conducted by a team of researchers from Albert Einstein College of Medicine in New York, the U.S. found that the modified bacteria can serve as a protection from lung disease, further expected to provide anti-causing bacteria tuberculosis. Uniquely, the bacterium that has been modified still has family ties of the bacterium that causes tuberculosis (Mycobacterium Tuberculosis) itself.
The results of a study published in Nature Medicine reports on 4 September 2011 and were investigating a group of genes called ESX-3, which is found in all variants of Mycobacterium in which the gene has a function in the performance of the bacteria to evade the immune system.
Research conducted by Kari Ann Sweeney, et al., Was found in kinship bacteria, Mycobacterium tuberculosis cannot survive without the ESX-3, but the ‘cousin’, Mycobacterium Smegmatis, capable. The researchers modified by deleting Smegmatis Mycobacterium ESX-3 gene was then injected into mice as experimental. Found from these actions within 3 days the mice had been cleared of bacteria in the lungs and kidneys.
Although research is still in very early stages, and the potential development of new vaccines are more effective than the results of these studies have not been so promising, the initial step of the study hopes to save millions of tuberculosis patients in the world.
Answering these circumstances, on other occasions in Hyderabad, India, has made a cooperation agreement between the World Health Organization (WHO) and International Pharmaceutical Federation (FIP) in the framework of the role of pharmaceutical companies have committed in the treatment of tuberculosis, on Monday (5 / 9) then. “Pharmaceuticals can be ‘gatekeepers’ to the vital point of tuberculosis services. WHO welcomes the opportunity of collaboration with pharmaceutical federation network even further to help tuberculosis patients by improving access and ease of handling and care to the needy, “said WHO Assistant Director for HIV / AIDS, Tuberculosis, Malaria and Tropical Diseases, Dr. Hiroki Nakatani opening speech at the signing ceremony of cooperation agreement is.
Similar positive remarks echoed by the President of the FIP participate, Dr. Michel Buchmann, “Now the area of pharmacy becomes more widespread role in the development and use of anti- tuberculosis drugs, this Cooperation Agreement also has a focus on pharmacy’s role is more specialized and direct involvement in the treatment of TB patients. FIP will support the WHO and health authorities of each country in an attempt to nationalize the anti-TB program. ”
In a world scale, according to WHO data, tuberculosis itself into position 7 of the top 10 killers in the world with a contribution of a number of human souls 1.7 million per year. On the other hand, the only existing vaccine of tuberculosis is BCG-less-effective performance. Performance results of the BCG vaccine have varied, ranging from 0% to 80% effectiveness of the various results in parts of the world. Not to mention the issue of potential new problems given the BCG vaccine to persons with HIV.
